Results 111 to 120 of about 35,587 (239)

Evaluation of risk factors predicting chemotherapy-related nausea and vomiting : results from a european prospective observational study

, 2014
Context Demographic, personal, clinical, and behavioral factors predicting chemotherapy-induced nausea and vomiting (CINV) have been assessed in the past, but inconsistencies exist in the literature, studies have methodological shortcomings, and many ...
Gu, A, Novoa, S. A., Gu, A., Molasiotis, A., Isambert, N, Aapro, M., Gascon, P, Isambert, N., Aapro, M, Roila, F, Roila, F., Gascon, P., Molassiotis, A, Burke, TA, Dicato, M., Dicato, M, Novoa, SA, Burke, T. A.   +17 more
core   +1 more source

Understanding the Symptom Burden of Complex Skull Base Tumors From the Patient's Perspective

Head &Neck, Volume 48, Issue 10, Page 2720-2732, October 2026.
ABSTRACT Background Symptom burden of skull base tumor (SBT) patients, especially those undergoing multimodality treatment, is poorly understood. We aim to understand symptom burden in this patient group using the core module the MD Anderson Symptom Inventory (MDASI).
Shirley Y. Su, Matheus Sewastjanow‐Silva, Jack Phan, Marc‐Elie Nader, Shaan M. Raza, Franco DeMonte, Paul W. Gidley, Ehab Y. Hanna, Loretta A. Williams   +8 more
wiley   +1 more source

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy

, 2009
Rudolph M NavariIndiana University School of Medicine South Bend, South Bend, IN USAAbstract: Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life.
Rudolph M Navari
core  

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Hematologic Toxicities and Determinants Among Patients With Breast Cancer Treated With Doxorubicin–Cyclophosphamide Followed by Paclitaxel in Northwest Ethiopia: A Retrospective Cohort Study

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Hematologic toxicities are common during breast cancer chemotherapy, but data from Ethiopia are limited. This study assessed hematologic toxicities and associated factors among patients treated with doxorubicin‐cyclophosphamide followed by paclitaxel (ACT) regimen in Northwest Ethiopia.
Tegenu Chanie Tesfaye, Rahel Belete Abebe, Gashaw Binega Mekonnen, Ephrem Tafesse Teferi, Mekonnen Melkie Bizuneh, Ashenafi Kibret Sendekie, Tigabu Eskeziya Zerihun, Desalegn Addis Mussie, Abel Temeche Kassaw, Samuel Agegnew Wondm   +9 more
wiley   +1 more source

An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries

, 2015
Background: Chemotherapy-induced nausea and vomiting (CINV) has been commonly reported as one of the most distressing adverse effects among treated patients with cancer.
Nazarena Cataldo, Marco Turini, Pierfrancesco Ruffo, Claudio Ripellino, Vittoria Piovesana   +4 more
core   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination

, 2016
Piotr K JanickiDepartment of Anesthesiology and Perioperative Medicine, Milton S Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA, USAPurpose: The purpose of this review is to summarize and discuss the recently ...
Janicki PK
core  

Chemotherapy-Induced Nausea and Vomiting #285 [PDF]

Journal of Palliative Medicine, 2014
Nishant, Tageja, Hunter, Groninger
openaire   +2 more sources

Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

The Laryngoscope, Volume 136, Issue 10, Page 4279-4289, October 2026.
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K. Evans, Hong‐Ho Yang, Christopher Dann, Dipti Sajed, Maie A. St. John   +7 more
wiley   +1 more source